Loading
A phase 1/2 trial of Docetaxel, Toripalimab, Carboplatin, Niraparib and Lenvatinib in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06682780 by LaNova Medicines Limited, with 320 participants planned, started 2025-09-17 and due to reach its primary completion in 2028-12-25. Interventions recorded: LM-2417, Docetaxel, Toripalimab/Tirelizumab, Carboplatin, Niraparib and Lenvatinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares LaNova Medicines, Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Docetaxel, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/